Literature DB >> 12200765

Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas.

Ehab A Abu-Basha1, Sirintorn Yibchok-Anun, Walter H Hsu.   

Abstract

The purpose of this study was to investigate the glucose dependency of arginine vasopressin (AVP)-induced insulin, glucagon, and somatostatin release from the perfused rat pancreas. AVP (30 or 300 pmol/L) was tested in the presence of a glucose concentration of 0, 1.4, 5.5 (basal level), or 20 mmol/L. The rates of insulin release at 0 and 1.4 mmol/L glucose were approximately 70% to 80% and 60% to 70% less, respectively, than that at the baseline level. AVP (30 or 300 pmol/L) failed to change insulin release at 0 and 1.4 mmol/L glucose. At the basal glucose level, AVP (300 pmol/L) induced a biphasic insulin release, a peak followed by a sustained phase. In addition, the combination of glucose (20 mmol/L) and AVP (300 pmol/L) induced a higher insulin peak and sustained phase than 20 mmol/L glucose alone. The rates of glucagon release at 0 and 1.4 mmol/L glucose were about 3- and 2-fold more, respectively, than that at the baseline level. At 0 and 1.4 mmol/L glucose, both 30 and 300 pmol/L AVP caused a higher glucagon peak and sustained phase than 0 and 1.4 mmol/L glucose alone. At the basal glucose level, AVP (30 or 300 pmol/L) induced a biphasic glucagon release, a peak followed by a sustained phase. The rate of glucagon release at 20 mmol/L glucose was approximately 60% to 70% less than that at the baseline level. When AVP (300 pmol/L) was administered in 20 mmol/L glucose, it induced a transient glucagon peak, which was 2.4-fold of the baseline level. At all glucose concentrations tested, AVP (30 or 300 pmol/L) failed to change somatostatin release. These results suggested that (1) hypoglycemia directly increases glucagon and decreases insulin release; (2) AVP induces insulin and glucagon release by a direct action on beta and alpha cells, respectively; (3) AVP induces insulin and glucagon release in a glucose-dependent manner-the higher the glucose concentration, the greater the enhancement of AVP-induced insulin release, whereas the lower the glucose concentration, the higher the enhancement of AVP-induced glucagon release; and (4) alpha cells are more sensitive to AVP than beta cells in hormone release. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200765     DOI: 10.1053/meta.2002.34052

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  28 in total

Review 1.  The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.

Authors:  Saptarshi Bhattacharya; Sanjay Kalra; Deep Dutta; Deepak Khandelwal; Rajiv Singla
Journal:  Eur Endocrinol       Date:  2019-10-18

2.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor.

Authors:  Yoko Fujiwara; Masami Hiroyama; Atsushi Sanbe; Toshinori Aoyagi; Jun-Ichi Birumachi; Junji Yamauchi; Gozoh Tsujimoto; Akito Tanoue
Journal:  J Physiol       Date:  2007-08-02       Impact factor: 5.182

Review 3.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

Review 4.  Brain to bone: What is the contribution of the brain to skeletal homeostasis?

Authors:  Anna Idelevich; Roland Baron
Journal:  Bone       Date:  2018-05-16       Impact factor: 4.398

5.  Plasma copeptin and the risk of diabetes mellitus.

Authors:  Sofia Enhörning; Thomas J Wang; Peter M Nilsson; Peter Almgren; Bo Hedblad; Göran Berglund; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Eero Lindholm; Leif Groop; Valeria Lyssenko; Marju Orho-Melander; Christopher Newton-Cheh; Olle Melander
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

6.  Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats.

Authors:  Christopher Taveau; Catherine Chollet; Ludovic Waeckel; Dorinne Desposito; Daniel G Bichet; Marie-Françoise Arthus; Christophe Magnan; Erwann Philippe; Valerie Paradis; Fabienne Foufelle; Isabelle Hainault; Sofia Enhorning; Gilberto Velho; Ronan Roussel; Lise Bankir; Olle Melander; Nadine Bouby
Journal:  Diabetologia       Date:  2015-01-27       Impact factor: 10.122

Review 7.  Water intake keeps type 2 diabetes away? Focus on copeptin.

Authors:  Giovanna Muscogiuri; Luigi Barrea; Giuseppe Annunziata; Martina Vecchiarini; Francesco Orio; Carolina Di Somma; Annamaria Colao; Silvia Savastano
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

8.  SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.

Authors:  Y Lytvyn; P Bjornstad; A Katz; S K Singh; L C Godoy; L T Chung; C L Vinovskis; L Pyle; R Roussel; B A Perkins; D Cherney
Journal:  Diabetes Metab       Date:  2019-12-06       Impact factor: 6.041

9.  Overlapping genes in Nalp6/PYPAF5 locus encode two V2-type vasopressin isoreceptors: angiotensin-vasopressin receptor (AVR) and non-AVR.

Authors:  Victoria L M Herrera; Pia Bagamasbad; Tamara Didishvili; Julius L Decano; Nelson Ruiz-Opazo
Journal:  Physiol Genomics       Date:  2008-04-15       Impact factor: 3.107

10.  Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community.

Authors:  Ronan Roussel; Ray El Boustany; Nadine Bouby; Louis Potier; Frédéric Fumeron; Kamel Mohammedi; Beverley Balkau; Jean Tichet; Lise Bankir; Michel Marre; Gilberto Velho
Journal:  J Clin Endocrinol Metab       Date:  2016-04-06       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.